REACTINE® Extra Strength Rapid Dissolve 10 mg
Orally disintegrating tablets for allergic rhinitis
Temporarily relieves nasal and non-nasal symptoms associated with seasonal and perennial allergic rhinitis:
Runny nose
Sneezing
Tearing and redness of the eyes
Itching of the nose or throat
Nasal congestion and stuffiness
Post-nasal discharge
Active Ingredient (in each chewable tablet):
Cetirizine HCl 10 mg
Inactive Ingredients:
Animo methacrylate copolymer, anhydrous citric acid, colloidal silicon dioxide, crospovidone, flavours, hydroxylpropyl cellulose, magnesium stearate, mannitol, microcrystalline cellulose, sodium bicarbonate, sodium starch glycolate, sucralose
Adults and children 12 years and over:
One 10 mg orally disintegrating tablet, once daily
Severe skin reactions such as generalized exanthematous pustulosis (AGEP) have been reported very rarely with cetirizine-containing products. This may exhibit an early or delayed onset with numerous small, mostly non-follicular pustules on the skin. Patients should be carefully monitored. Patients should discontinue use and consult a physician if symptoms persist, worsen, or if new symptoms occur.
REACTINE® is contraindicated in patients who have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing hydroxyzine, or to piperazine derivatives, or in patients with severe renal impairment (less than 10 mL/min clearance).
If drowsiness occurs, patients should be advised to not drive or operate machinery and to avoid concurrent of use of REACTINE® with sedating substances such as alcohol and other medications including: anti-anxiety medications, sleep aids, antihistamines, antidepressants, muscle relaxants, or prescription analgesics.
The most common side effects associated with REACTINE® are headache (7.42%), somnolence (9.63%) and dry mouth (2.09%). Occasional instances of transient, reversible hepatic transaminase elevations have occurred during REACTINE® therapy, without evidence of jaundice, hepatitis or other clinical findings.
There are no adequate and well-controlled studies in pregnant women. Until such data become available, REACTINE® should not be used during pregnancy, unless advised otherwise by a physician.
The extent of excretion in human milk is unknown. Therefore, use of REACTINE® in nursing mothers is not recommended, unless directed otherwise by a physician.
Overdose has been reported with REACTINE®. For management of a suspected overdose, your patients should contact their regional Poison Control Centre.
Store between 15° to 30°C.
Questions? Call 1-87-REACTINE (1-877-322-8463).
This website contains current product information and may differ from the information on the product packaging you may have. If you have any questions, please contact 1-87-REACTINE (1-877-322-8463).
